Role of immunosuppressive therapy in rheumatic diseases concurrent with COVID-19

Ann Rheum Dis. 2020 Jun;79(6):737-739. doi: 10.1136/annrheumdis-2020-217460. Epub 2020 Apr 15.

Authors

Chenyang Lu^#¹, Shasha Li^#², Yi Liu³

Affiliations

¹ Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
² Department of Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA.
³ Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, Sichuan, China Yi2006liu@163.com.

^# Contributed equally.

PMID: 32295789
DOI: 10.1136/annrheumdis-2020-217460

No abstract available

Keywords: antirheumatic agents; cytokines; inflammation.

Publication types

Review
Comment

MeSH terms

Betacoronavirus
COVID-19
Coronavirus Infections
Humans
Kidney Transplantation*
Pandemics
Pneumonia, Viral*
Rheumatic Diseases*
SARS-CoV-2